 |
Dendreon Announces Presentation of PROVENGE Data at the 2012 American Society of Clinical Oncology Annual Meeting
May 16, 2012
|
63.6 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
May 16, 2012--Dendreon Corporation (NASDAQ:DNDN)
today announced the following PROVENGE® (sipuleucel-T) data will be
presented at the American Society of Clinical Oncology (ASCO) Annual
Meeting American Society of Clinical Oncology (ASCO) Annual Meeting
taking place June 1...
|
|
Dendreon Reports Net PROVENGE Product Revenues of $82 Million, Achieved 6.5% Quarter-Over-Quarter Growth
May 7, 2012
|
21.0 KB |
|
| |
-- Conference Call to be Hosted May 7, 2012 at 4:30 p.m. ET/1:30 p.m.
PT —
SEATTLE--(BUSINESS WIRE)--
May 7, 2012--Dendreon Corporation (Nasdaq:DNDN) today reported results
for the quarter ended March 31, 2012. Net product revenue for the
quarter was $82.0 million compared to ...
|
|
Dendreon to Host Conference Call on May 7 to Announce First Quarter Financial Results and Webcast Presentations at Upcoming Conferences
Apr 9, 2012
|
11.6 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
April 9, 2012--Dendreon Corporation (Nasdaq:DNDN) today announced that
management will host a conference call on Monday, May 7, 2012, at 4:30
p.m. EDT to review first quarter financial results.
Access to the discussion may be obtained as follows:
...
|
|
Dendreon Announces Webcast Presentation at Upcoming Conferences
Mar 5, 2012
|
9.5 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
March 5, 2012--Dendreon Corporation (Nasdaq: DNDN) today announced that
management will present at the following conferences:
Cowen and Company 32nd Annual Health Care Conference in Boston, MA, on
March 7, 2012, at 8:00 a.m. ET
...
|
|
Dendreon Announces Executive Appointments
Feb 28, 2012
|
14.3 KB |
|
| |
— Joe DePinto Named Executive Vice President, Global Commercial
Operations —
— Robert S. Poulton Named Executive Vice President, Technical
Operations —
— Christine Mikail Named Executive Vice President, Corporate
Development, General Counsel, ...
|
|
Dendreon Reports Fourth Quarter and 2011 Year End Financial Results
Feb 27, 2012
|
23.5 KB |
|
| |
— Conference Call to be Hosted February 27, 2012 at 9:00 a.m. ET/6:00
a.m. PT —
SEATTLE--(BUSINESS WIRE)--
February 27, 2012--Dendreon Corporation (Nasdaq: DNDN) today reported
results for the year and quarter ended December 31, 2011. Product
revenue for the year ended D...
|
|
Dendreon Announces New Time for Fourth Quarter and Year-End Financial Results Conference Call and Webcast Presentations at Upcoming Conferences
Feb 22, 2012
|
11.8 KB |
|
| |
Call to be held on Monday, February 27, 2012, at 9:00 a.m. ET
SEATTLE--(BUSINESS WIRE)--
February 22, 2012 — Dendreon Corporation (Nasdaq: DNDN) today
announced that management will host a conference call on Monday,
February 27, 2012, at 9:00 a.m. ET to review fourth quarter and year-e...
|
|
Dendreon to Host Conference Call on February 27 to Announce Fourth Quarter and Year-End Financial Results and Webcast Presentations at Upcoming Conferences
Feb 1, 2012
|
11.5 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
February 1, 2012 — Dendreon Corporation (Nasdaq: DNDN) today
announced that management will host a conference call on Monday,
February 27, 2012, at 4:30 p.m. ET to review fourth quarter and year-end
financial results.
Access to the discussion may be obtain...
|
|
Dendreon Announces CEO and Chairman Succession Plan
Feb 1, 2012
|
18.7 KB |
|
| |
John H. Johnson Elected President, Chief Executive Officer and
Chairman-Elect, Dr. Mitchell H. Gold Elected Executive Chairman
Company to Hold Conference Call Today at 9:00 a.m. ET/6:00 a.m. PT
SEATTLE--(BUSINESS WIRE)--
February 1, 2012 — Dendreon Corporation (Nasdaq: ...
|
|
Dendreon Announces Presentation of PROVENGE Data at the ASCO 2012 Genitourinary Cancers Symposium
Jan 31, 2012
|
57.5 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
January 31, 2012 — Dendreon Corporation (NASDAQ: DNDN)
today announced the following PROVENGE® data will be
presented at the American Society of Clinical Oncology 2012
Genitourinary Cancers Symposium (ASCO-GU), taking place February 2-4,
2012 in San Francisco, Califo...
|
|
Dendreon Announces Fourth Quarter Revenues and Update on Commercialization
Jan 5, 2012
|
13.1 KB |
|
| |
— Company Reports Gross PROVENGE Revenues of Approximately $82M in
Q4, Gross PROVENGE Revenues of Approximately $228M in 2011 —
SEATTLE--(BUSINESS WIRE)--
Dendreon Corporation (Nasdaq: DNDN) today announced revenue for the
fourth quarter ended December 31, 2011, reporting gross p...
|
|
Dendreon Announces Webcast Presentation at J.P. Morgan Healthcare Conference
Jan 4, 2012
|
9.1 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
Dendreon Corporation (NASDAQ:DNDN) today announced that management will
present at the 29th Annual J.P. Morgan Healthcare Conference in San
Francisco on January 9, 2012, at 3:30 p.m. PT.
The presentation will be audio webcast live and available for replay
from D...
|
|
Dendreon Agrees to Sell VICTRELIS™ (boceprevir) Royalty Interest for $125 Million
Dec 6, 2011
|
12.7 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
Dendreon Corporation (NASDAQ:DNDN) today announced that it has agreed to
sell for $125 million in cash its royalty interest related to
intellectual property licensed to Schering-Plough Ltd. and Schering
Corporation (collectively Schering, each now a wholly owned subsidiary
of M...
|
|
Dendreon Announces Webcast Presentation at Upcoming Conferences
Nov 22, 2011
|
9.2 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
Dendreon Corporation (Nasdaq:DNDN) today announced that management will
present at the following conferences:
Deutsche Bank BioFEST in Boston, Massachusetts on December 5, 2011 at
9:30 am ET
NASDAQ OMX 27th Investor Program in...
|
|
Dendreon Announces the Centers for Medicare and Medicaid Services (CMS) Will Now Cover Infusion Costs Associated with the Administration of PROVENGE
Nov 21, 2011
|
13.0 KB |
|
| |
CMS Updates Coverage Policy to Reimburse for Costs Associated with
the Infusion
SEATTLE--(BUSINESS WIRE)--
Dendreon Corporation (NASDAQ:DNDN) today announced the Centers for
Medicare and Medicaid Services (CMS) updated their coverage policy to
now cover the infusion costs associated...
|
|
Dendreon Announces Election of Dennis M. Fenton to Board of Directors
Nov 8, 2011
|
10.2 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
Dendreon Corporation (Nasdaq: DNDN) today announced that Dennis M.
Fenton has been elected to the Company's Board of Directors, effective
November 8, 2011. Dr. Fenton has 30 years of pharmaceutical and
biotechnology experience, including over two decades at Amgen, Inc.,
where h...
|
|
Dendreon Reports Third Quarter 2011 Financial Results
Nov 2, 2011
|
24.8 KB |
|
| |
— Gross Product Revenue of Approximately $66MM in Q3 —
SEATTLE--(BUSINESS WIRE)--
Dendreon Corporation (NASDAQ:DNDN) today reported results for the third
quarter ended September 30, 2011. Net revenue for the quarter ended
September 30, 2011 was $64.3 million compared to $20.2 mil...
|
|
Dendreon Announces Webcast Presentations at Upcoming Conferences
Oct 20, 2011
|
9.1 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
Dendreon Corporation (Nasdaq:DNDN) today announced that management will
present at the following conferences:
Credit Suisse Healthcare Conference in Phoenix, Arizona on November 9,
2011 at 8:00 a.m. MT
Lazard Healthcare Confer...
|
|
Dendreon Begins Enrollment in Phase 2 Neu-ACT Trial for Second Active Cellular Immunotherapy Product Candidate, DN24-02
Oct 17, 2011
|
17.0 KB |
|
| |
-- First Patient Enrolled in HER2+ bladder carcinoma study --
SEATTLE--(BUSINESS WIRE)--
Dendreon Corporation (Nasdaq: DNDN) today announced that the company has
begun enrolling patients into a Phase 2 trial for DN24-02, Dendreon's
investigational active cellular immunotherapy being evaluate...
|
|
Dendreon to Host Conference Call on November 2, 2011 to Announce Third Quarter 2011 Financial Results
Oct 5, 2011
|
10.0 KB |
|
| |
SEATTLE--(BUSINESS WIRE)--
Dendreon Corporation (NASDAQ:DNDN) today announced that management will
host a conference call on Wednesday, November 2, 2011 at 4:30 p.m. ET to
review the third quarter 2011 financial results.
Access to the discussion may be obtained as follows:
...
|
|
|
delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz